Table 2.
Baseline characteristics of unmatched and propensity core–matched cohort
| Unmatched cohort |
Matched cohort |
|||||
|---|---|---|---|---|---|---|
| Primary prophylaxis (n = 178) | Secondary prophylaxis (n = 315) | P value | Primary prophylaxis (n = 133) | Secondary prophylaxis (n = 133) | P value | |
| Male | 158 (88.7%) | 271 (86.0%) | 0.3860 | 117 (88.0%) | 118 (88.7%) | 0.8485 |
| Age, years | 70.0 ± 8.7 | 66.6 ± 11.1 | <0.001 | 69.1 ± 8.5 | 70.6 ± 8.8 | 0.0767 |
| Single-chamber ICD | 28 (15.7%) | 57(18.1%) | 0.5043 | 25 (18.7%) | 22 (16.5%) | 0.6269 |
| CRTD | 95 (53.3%) | 55 (17.4%) | <0.001 | 50 (37.6%) | 46 (34.5%) | 0.6096 |
| NYHA functional class III or IV | 76 (42.6%) | 67 (21.2%) | <0.001 | 44 (33.1%) | 44 (33.1%) | 1.0000 |
| LVEF, % | 30.5 ± 10.8 | 39.1 ± 13.7 | <0.001 | 31.9 ± 11.4 | 33.3 ± 11.4 | 0.1595 |
| BNP, pg/mL | 513.1 ± 570.7 | 493.1 ± 831.1 | 0.3859 | 476.9 ± 518.6 | 546 ± 817 | 0.2222 |
| Hb, g/dL | 12.4 ± 2.0 | 12.2 ± 1.9 | 0.0778 | 12.7 ± 2.0 | 12.1 ± 2.0 | 0.0079 |
| HT | 110 (61.7%) | 168 (53.3%) | 0.0687 | 83 (62.4%) | 88 (66.2%) | 0.5223 |
| DL | 81 (45.5%) | 144 (45.7%) | 0.9644 | 66 (49.6%) | 63 (47.3%) | 0.7128 |
| DM | 79 (44.3%) | 126 (4.0.0%) | 0.3430 | 55 (41.4%) | 59 (44.4%) | 0.6202 |
| Stroke | 18 (10.1%) | 29 (9.2%) | 0.7422 | 13 (9.8%) | 10 (7.5%) | 0.5128 |
| HU | 32 (17.9%) | 43 (13.6%) | 0.1989 | 26 (19.5%) | 27 (20.3%) | 0.8780 |
| PAD | 6 (3.3%) | 16 (5.1%) | 0.3775 | 3 (2.3%) | 8 (6.0%) | 0.1236 |
| 3VD or LMT | 56 (31.4%) | 80 (25.3%) | 0.1479 | 39 (29.3%) | 37 (27.8%) | 0.7860 |
| Diuretic agent | 130 (73.0%) | 178 (56.5%) | <0.001 | 98 (73.6%) | 87 (65.4%) | 0.1428 |
| β-blocker | 120 (67.4%) | 186 (59.0%) | 0.2878 | 89 (66.9%) | 84 (63.2%) | 0.5203 |
| ACE-I/ARB | 124 (69.6%) | 199 (63.1%) | 0.1455 | 93 (69.9%) | 78 (58.6%) | 0.0549 |
| Antiplatelet agent | 147 (82.5%) | 253 (80.3%) | 0.5366 | 109 (81.9%) | 107 (80.4%) | 0.7536 |
| Anticoagulant agent | 53 (29.7%) | 87 (27.6%) | 0.6101 | 45 (33.8%) | 35 (26.3%) | 0.1812 |
| Class III antiarrhythmic drug | 57 (32.0%) | 197 (62.5%) | <0.001 | 42 (31.5%) | 90 (67.6%) | <0.001 |
Values are presented as mean ± SD or n (%).
ACE-I = angiotensin-converting enzyme inhibitors; ARB = angiotensin II receptor; BNP = brain natriuretic peptide; CRTD = cardiac resynchronization therapy with defibrillator; DL = dyslipidemia; DM = diabetes mellitus; Hb = hemoglobin; HT = hypertension; HU = hyperuricemia; ICD = implantable cardioverter-defibrillator; LMT = left main trunk; LVEF = left ventricular ejection fraction; NYHA = New York Heart Association; PAD = peripheral arterial disease; 3VD = 3-vessel disease.